Nicht aus der Schweiz? Besuchen Sie lehmanns.de
Drugs and a Methodological Compendium -

Drugs and a Methodological Compendium

From bench to bedside
Buch | Hardcover
425 Seiten
2023 | 2023 ed.
Springer Verlag, Singapore
978-981-19-7951-4 (ISBN)
CHF 299,55 inkl. MwSt
  • Versand in 15-20 Tagen
  • Versandkostenfrei
  • Auch auf Rechnung
  • Artikel merken
This book provides a meticulous view on methodological drug discovery and development insights from bench to bedside. The current book threads almost each step encompassing drug the discovery and development of a molecule. The chapters focus on computational modus operandi, pharmacological optimization approaches, modern high-throughput screening methods and in-vitro procedures, role of structural biologists in drug discovery and development,  medicinal chemistry approaches for drug design, formulation and drug delivery, in-vivo evaluations of candidate molecules, clinical trial procedures and others. The book also covers specific case studies, regulatory approval proceedings, and industrial view point alongside the aforementioned conceptual layout. And at the same time, the volume integrates medical, biological, medicinal, pharmacological and computational streams, and it is suggested as an ideal guideline to a wide audience including molecular biologists, biochemist, pharmacologists, medicinal chemist, toxicologists, drug discovery and development researchers, and all other students interested in these disciplines.

Vikrant Singh Rajput graduated with B. Tech in Biotechnology (2010) from Amity University, Noida, UP, India, a Ph.D in Biological Science from CSIR-Indian Institute of Integrative Medicine, Jammu, J&K, India (2017). He was awarded postdoctoral fellowship from Indian Institute of Technology (IIT) Roorkee and Young Scientist Award/Research grant from Department of Health Research (Govt. of India). He has also held different positions like Adhoc Faculty at National Institute of Technology (NIT) Raipur, Project scientist at Biosafety Support Unit, Regional Centre for Biotechnology, Faridabad and Scientist at Foundation for Neglected Diseases Research, Bengaluru. He currently works as Assistant Professor at Dept. of Biomedical Engineering, Central University of Rajasthan Ajmer. Areas of interest: TB biology; TB and anti-bacterial drug discovery; Technologies evaluating PK/PD of TB drugs, Combatting drug resistance; Novel drug targets; Computational drug discovery and immunoinformatics. Ashish Runthala graduated with M.Sc. in Biological Science (2005) from BITS Pilani, Rajasthan, India. Meanwhile qualifying the National Eligibility test (NET), he pursued the M.E. in Biotechnology (2008) here and completed Ph.D in Computational Biology in 2016. He was awarded the Ucchayatar Avishkar Yojana (UAY) in 2017 from Indian Institute of Science. Starting his academic responsibilities at BITS Pilani from 2005, he has held several positions viz. Teaching Assistant, Assistant Lecturer, Lecturer and Visiting Faculty. He has also worked at Presidency University Bangalore as an Assistant Professor. He is currently working as an Associate Professor at KL University, Vijayawada, and is doing research on developing the functionally improved enzymes of the DXP pathway for enhancing the overall yield of the pathway. Areas of interest: Computational algorithms; Bioinformatics; Protein structure prediction; Enzyme design; Decoding active site; Designing thermostable enzyme.

Chapter 1.Computational and informatics methodologies in Drug Discovery, with focus on Natural Products.-  Chapter 2.Structural biology an essential tool for Drug discovery and Development.- Chapter 3.Bioactivity guided fractionation and identification of bioactive molecules: A basic method in drug discovery.- Chapter 4.In–vitro methodologies for the safety assessment of drugs.- Chapter 5.In-vivo models for evaluation of Drug efficacy: Demand and Challenges.- Chapter 6.Preclinical In vivo Drug Development Studies: Limitations, Model Organisms and Techniques.- Chapter 7.Peptide Based Therapeutics and Drug Delivery Systems.- Chapter 8.Basics of Clinical Drug Development: Clinical Trial and Drug Development.- Chapter 9.Trailblazing contemporary frameworks for drug repurposing: A saga on drugs’ expedition to disinter the veiled destiny.- Chapter 10.Small molecules as promising tool for targeted cancer therapies: an overview of 21st century.- Chapter 11.Nanoparticles for Targeted DrugDelivery Systems with Cancer Therapy in Perspective.- Chapter 12.Biomimetic approach for the controlled drug delivery through 3D bioactive scaffolds: A novel strategy for tissue engineering applications.- Chapter 13.Perspectives on anti-tuberculosis drug discovery.- Chapter 14.Cofactor-Receptor interactions based pharmacophore design for development of novel inhibitors: A case study against Tuberculosis.- Chapter 15.Insilico identification of potential antivirals against SARS-CoV2 main protease and RBD of spike protein – A Drug Repurposing Approach.- Chapter16.Anti-malarial drug discovery and development: from bench to bedside.

Erscheinungsdatum
Zusatzinfo 1 Illustrations, black and white; XV, 425 p. 1 illus.
Verlagsort Singapore
Sprache englisch
Maße 155 x 235 mm
Themenwelt Medizin / Pharmazie
Naturwissenschaften Biologie Genetik / Molekularbiologie
Naturwissenschaften Chemie
Technik Umwelttechnik / Biotechnologie
ISBN-10 981-19-7951-0 / 9811979510
ISBN-13 978-981-19-7951-4 / 9789811979514
Zustand Neuware
Informationen gemäß Produktsicherheitsverordnung (GPSR)
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich
50 Meilensteine der Genetik

von Jonathan Weitzman; Matthew Weitzman

Buch | Hardcover (2022)
Librero b.v. (Verlag)
CHF 13,90